Psoriasis Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00$ 8,900.00

Psoriasis Drugs Market: By Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, and Topical Therapies), Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, and Other Mechanisms of Action), Route of Administration (Oral, Parenteral, and Topical), and Geography (North America, Europe, Asia-Pacific, South America and, The Middle East & Africa) and Forecast to 2028

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Psoriasis Drugs Market size is estimated to be valued at USD 12,000 million in 2021 and is poised to grow at a significant CAGR of 7% over 2022–2028. Psoriasis is an immune-mediated illness that results in a skin condition caused by systemic inflammation. The psoriasis drugs market players will benefit from an increase in psoriasis research and pipeline therapeutics and an increase in disease burden and demand for psoriasis treatments in emerging economies. For instance, in November 2020, Bristol Myers Squibb Presented Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis. Rising awareness programs about psoriasis disease and treatment alternatives, increased reimbursement support, and increased research and development with the introduction of biologics and biosimilars are all aspects that are influencing the psoriasis pharmaceuticals market and boosting sales growth. Furthermore, prominent market players engage in various business strategies such as product launches to grow their product portfolios and gain a competitive advantage. For example, in July 2020, Fujifilm Kyowa Kirin Biologics received regulatory approval in Japan to manufacture and market the first adalimumab biosimilar for treating psoriasis, Vulgaris arthritic psoriasis, and pustular psoriasis.

Recent Market Developments:

In January 2022, AbbVie announced the U.S. Food and Drug Administration (FDA) had approved SKYRIZI (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA). This systemic inflammatory disease affects the skin and joints and impacts approximately 30 % of patients with psoriasis.

In December 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved Otezla (apremilast) to treat adult patients with plaque psoriasis candidates for phototherapy or systemic therapy.

Psoriasis Drugs Market

MARKET SUMMARY
-
7% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 7%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Psoriasis Drugs Market

  • The psoriasis drugs market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The psoriasis drugs market is segmented on the type of treatment, mechanism of action, route of administration, and geography.
Key Players
  • Abb Vie Inc.
  • Eli Lilly and Company
  • Boehringer Ingelheim GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Novartis International Ltd.
Psoriasis Drugs Market

Dynamics

The rising incidence of psoriasis worldwide has produced a significant demand for safe and effective treatments. This has driven manufacturing businesses to engage in research and development initiatives to develop new psoriasis treatment options. The market is driven by a strong product pipeline and growing regulatory approvals for products like Stelara (Janssen Pharmaceuticals) and Cimzia (UCB S.A.). However, the high medical costs associated with psoriasis therapy are one of the critical issues limiting demand for psoriasis medications. Increased spending on medication development for regulatory approvals and the patent filing procedure, which manufacturers are continually seeking to develop novel biological therapies, also limit the market growth. The lack of awareness regarding psoriasis and its related comorbidities is a prominent market restraint.


North-America Got Significant Share

Psoriasis Drugs Market

The psoriasis drugs market in North America is likely to hold the highest revenue share in 2022, and in the following years, it is predicted to increase rapidly. Psoriasis is becoming more prevalent, and people are becoming more aware of it, which has boosted the market in the region. The call will be fuelled by the development of robust healthcare reforms in the United States, which will provide the patient population with increased access to medical treatment over the projected period. Europe holds a significant share of the global market. It is expected to grow at a high rate in the coming years due to the high prevalence of disease in the region, particularly in the United Kingdom, which has strongly surged the demand for therapeutic drugs.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Findings of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2016-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Psoriasis Drugs Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

  • Janssen Biotech Inc
  • Novartis International Ltd.
  • Amgen Inc, Pfizer Inc.
  • Takeda Pharmaceutical Company Ltd. Merck & Co Inc.
  • Abb Vie Inc.
  • Eli Lilly and Company
  • Boehringer Ingelheim GmbH
  • Sun Pharmaceutical Industries Ltd.

Description

Psoriasis Drugs Market size is estimated to be valued at USD 12,000 million in 2021 and is poised to grow at a significant CAGR of 7% over 2022–2028. Psoriasis is an immune-mediated illness that results in a skin condition caused by systemic inflammation. The psoriasis drugs market players will benefit from an increase in psoriasis research and pipeline therapeutics and an increase in disease burden and demand for psoriasis treatments in emerging economies. For instance, in November 2020, Bristol Myers Squibb Presented Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis. Rising awareness programs about psoriasis disease and treatment alternatives, increased reimbursement support, and increased research and development with the introduction of biologics and biosimilars are all aspects that are influencing the psoriasis pharmaceuticals market and boosting sales growth. Furthermore, prominent market players engage in various business strategies such as product launches to grow their product portfolios and gain a competitive advantage. For example, in July 2020, Fujifilm Kyowa Kirin Biologics received regulatory approval in Japan to manufacture and market the first adalimumab biosimilar for treating psoriasis, Vulgaris arthritic psoriasis, and pustular psoriasis.

Recent Market Developments:

In January 2022, AbbVie announced the U.S. Food and Drug Administration (FDA) had approved SKYRIZI (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA). This systemic inflammatory disease affects the skin and joints and impacts approximately 30 % of patients with psoriasis.

In December 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved Otezla (apremilast) to treat adult patients with plaque psoriasis candidates for phototherapy or systemic therapy.

Reviews

There are no reviews yet.

Be the first to review “Psoriasis Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX